Connect with us

Featured

Western Sierra Resource Corp (OTCMKTS: WSRC) Blue Sky Breakout as Subsidiary MSL Inks Enormous Contract to Restore the Twitchell Dam and Reservoir

Published

on

Western Sierra Resource Corp (OTCMKTS: WSRC) is rocketing up the charts taking out previous highs of $0.105 on Monday and is now on a blue-sky breakout. No strangers to big moves WSRC ran from $0.05 to $0.50 during the summer during the summer of 2021 before it dropped below $0.03 earlier this year. In October the stock took off and has been making higher highs and higher lows ever since. 

The big move on WSRC comes after the Company acquired 100% of Mitigation Solutions, LLC (MSL) In a stock and cash transaction. MSL’s first Mitigation Agreement as a WSRC Company is to restore the Twitchell Dam and Reservoir in Santa Barbara, California capacities at cost of from $1.5 Billion to $2 Billion under the final contract that was ratified by all parties on October 19, 2022. The Contract allows for adjustment in the scope and term of the project – over an anticipated completion schedule of 7 to 10 years. Gross revenue to the Company is estimated to average $200 million annually. Two additional projects are currently in queue.  

WSRC Thursday Update: WSRC saw a correction since hitting new highs of $0.132 earlier this week dipping below $0.10 briefly on Thursday before stabilizing over a dime where it is currently forming a new base. WSRC current price to beat is $0.132, a break over and WSRC could really take off into a new trading range. We gave the heads up on WSRC at the end of September as WSRC was moving up over its $0.03 base in our article here. We will be updating on WSRC so make sure you are subscribed to microcapdaily.com by entering your email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Western Sierra Resource Corp (OTCMKTS: WSRC) has a 115-year history as gold and silver mining company with projects in Arizona, Nevada, California, and Mexico. WSRC currently owns six precious metal reserves in Arizona. In 2014 the Company broadened its vision to include natural (and renewable) resources with its acquisition of water rights and associated infrastructure assets in Colorado for purposes of irrigating and cultivating industrial hemp; processing hemp for manufacture of various building products; and for construction of affordable homes utilizing hemp-based materials-among other beneficial uses. WSRC’s intent is to become a broad-based resource company with high value, income generating assets that include water conservation projects, real estate, agriculture, precious metals, helium, and associated “green” technologies. 

In September WSRC made an important acquisition which would change the course of the Company. They acquired 100% of the stock and assets of Mitigation Solutions, LLC (MSL) In a stock and cash transaction, MSL has become a wholly owned subsidiary of WSRC, providing the Company with capacity to mitigate water contamination, dam stabilization, and remediate sedimentation-affected large-scale water supplies for municipalities and Special Districts across the Country. MSL’s Principals joined WSRC’s management team, and brought with them decades of disaster response/relief and restoration experience to the Company to include hurricane damage; flood contaminated waterways; compromised lake, reservoir, and municipal water storage facilities; and water delivery system failure. In this capacity, Global Clean Water, Inc. has also contracted with MSL and WSRC to specifically address remediation of potable water contamination issues. 

MSL’s first Mitigation Agreement as a WSRC Company was executed between MSL and the Santa Maria Valley Water Conservation District (SMVWCD) in Santa Barbara County, CA. A Final Contract was ratified by all Parties on October 19, 2022. Under this final Contract, MSL will mitigate damage and restore the Twitchell Dam and Reservoir to its original holding capacities at cost of from $1.5 Billion to $2 Billion. The Contract allows for adjustment in the scope and term of the project – over an anticipated completion schedule of 7 to 10 years. Gross revenue to the Company is estimated to average $200 million annually. Two additional projects are currently in queue. 

Ratification of the Final Contract precipitates commencement of Phase I operations within seven (7) days, and continuous ramp-up over the next several months. The Company has secured $40 million in equipment financing and a $150 million Line of Credit for phased mobilization immediately available through institutional providers. 

To Find out the inside Scoop on WSRC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

WSRC

MSL will secure Federal reimbursement funding for SMVWCD from Infrastructure Investment and Jobs Act, The Inflation Reduction Act and the 2022 Omnibus Appropriations Bill through various Federal and State agencies, primarily the Federal Emergency Management Agency (FEMA), United States department of Agriculture (USDA), and the U.S. Department of Transportation (USDOT). Additional financial participation by other Federal and State Agencies is anticipated. 

Federal Funding for SMVWCD (as beneficiary) applies first to stabilization of the Twitchell Dam and restoration of the ~224,300-acre-foot (~73.07 billion gallon) Twitchell Reservoir. MSL will remove and repurpose approximately 40 to 60 million cubic yards of ash-contaminated and non-contaminated sediments from the Reservoir basin. This sediment has collected in the Reservoir over the last four decades and has vastly reduced the Reservoir ability to recharge the local groundwater and aquafer that local agriculture and food production depends on. Returning the Reservoir to its original holding capacity also allows the Twitchell Dam and Reservoir to function effectively as an essential flood control structure and source of water to fight wildfires. 

Secondly, the scope of the project encompasses mitigation of influent-contaminated sediments, water contamination, and preemptively addresses the deposit of eroding soils from upstream drainages to mitigate future adverse effects for the Reservoir and damage to the Dam that sustains it. Global Clean Water, Inc. (GCW) has contracted with both WSRC and MSL to address functions in each of the four (or more) phases of the Twitchell project. 

For More on WSRC Subscribe Right Now!

Currently trading at a $27 million market valuation WSRC OS is 312,136,648 and there is 111,263,126 shares in the float. The Company carries its water rights at $49 million on the balance sheet and they have $9.7 million in liabilities. WSRC is an exciting story developing in small caps, they just secured $25 million in funding, acquired Mitigation Solutions, LLLC and signed an agreement with the Santa Maria Valley Water Conservation District (SMVWCD) in Santa Barbara County, CA for the mitigation of Twitchell Dam and Reservoir. The Agreement has a value of $1.976 Billion payable over the 7-to-10-year term of the project-an estimated $200 million in average annual gross revenue. WSRC is quickly attracting a fast-growing shareholder base who are accumulating at current levels and swear this one goes way higher.  We will be updating on WSRC on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with WSRC.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in WSRC either long or short and we have not been compensated for this article.

Featured

Wearable Devices Ltd. (NASDAQ: WLDS) Breaking Boundaries with AI

Published

on

Israeli technology company Wearable Devices Ltd. (NASDAQ: WLDS) announced that the Mudra Band for Apple Watch is now available for pre-order on their website.

Israeli technology company Wearable Devices Ltd. (NASDAQ: WLDS), known for developing AI-powered touchless sensing wearables, has announced that their flagship consumer product, the Mudra Band for Apple Watch, is now available for pre-order on their website. The company has received thousands of pre-orders as they gear up for their first large-scale manufacturing batch.

In a remarkable turn of events, the company’s shares experienced an astounding surge of 265% at the time of writing, accompanied by a staggering total of 48 million shares being traded. Having operated under NASDAQ compliance standards since September of last year, the company has largely flown under the radar with relatively low trading volume. Currently, approximately 5.88 million shares are available for trading, a significant portion of which are closely held by insiders. The recent groundbreaking news marks a pivotal moment for the company, setting a trajectory for future growth as they assert its dominance in the realm of AI for wearable devices.

To Discover the Inside Scoop on WLDS, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The Mudra Band was initially designed to allow the touchless operation of the Apple Watch using neural signals. However, it has since expanded its features with Air-Touch, which enables users to operate various Apple devices through intuitive finger movements and hand gestures, eliminating the need for physical touch. The latest features also provide seamless device switching and toggling between iPhone, iPad, Mac computer, Apple TV, smart glasses, and mobile gaming devices.

Wearable Devices CEO, Asher Dahan, expressed his belief that the Mudra Band is setting a new standard for user interactions with connected devices, extended reality, and gaming. The company is scaling its marketing and support capabilities to meet the high demand for the product and aims to start shipping in the second half of 2023.

The Mudra Band is compatible with different models of the Apple Watch and is being extensively tested and approved by a global community of Apple enthusiasts. It is the ultimate aftermarket accessory for controlling Apple devices within their ecosystem.

Quick overview of the company

Wearable Devices Ltd. is a growth-oriented company that develops AI-based neural input interface technology for both consumer and business markets. In addition to the Mudra Band, they also offer the Mudra Inspire as a B2B product, providing businesses the same functionality and technology through licensing. The company aims to create disruptive technology that leverages AI and proprietary algorithms, software, and hardware to establish the input standard for the rapidly expanding Metaverse landscape in the tech industry.

More on the Mudra Brand and latest Event

Wearable Devices Ltd. (NASDAQ: WLDS) recently attended a big event called the TinyML Summit. They recently had the chance to show their technology firsthand and have users experience their award-winning aftermarket band for the Apple Watch – enabling touchless control of Apple products using subtle finger and wrist movements.

The tinyML Summit is a vibrant gathering that attracts a diverse range of professionals and enthusiasts from various industries. Engineers, developers, managers, executives, and founders involved in developing sensors, silicon, software, machine learning tools, or systems for the tiny ML (machine learning) market come together at this event. It also appeals to system designers and integrators seeking to incorporate low-power, low-cost machine learning into their devices and products across different verticals, such as consumer electronics, industrial applications, extended reality (XR), healthcare, and more.

On top of the band, the company also highlighted its multi-device functionality that allows for seamless control across not just the Apple watch but also other Apple devices like iPhones, iPads, Mac computers, and Apple TVs

As mentioned, the summit provides a dynamic platform for showcasing cutting-edge technology in machine learning on edge devices and fostering knowledge exchange among industry leaders. In the past year, the company behind this groundbreaking technology has meticulously fine-tuned its product, remaining relatively low-key as it devoted its efforts to perfecting its innovation. 

The company is strategically leveraging events like the tinyML Summit to gain exposure. The response has been remarkable, as the product has already generated tremendous buying interest, evident from the large pre-order numbers they are experiencing. This surge in interest signifies the excitement surrounding their offering and the anticipation of what this groundbreaking technology can achieve.

We will update you on WLDS when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Caro Sodar from Pixabay

Continue Reading

Featured

CohBar Inc. (NASDAQ: CWBR) and Morphogenesis Join Hands to Create TuHURA Biosciences

Published

on

Shares surged nearly 200% on CohBar, Inc. (NASDAQ: CWBR) as they entered a definitive agreement with Morphogenesis Inc.

Shares surged nearly 200% on CohBar, Inc. (NASDAQ: CWBR) as they entered a definitive agreement with Morphogenesis Inc. for an all-stock transaction to merge the two companies. The recent merger announcement has sparked a flurry of trading activity, resulting in a significant change in trading volume. Before the merger news, the average daily trading volume for CohBar stood at approximately 3.5K shares. However, at the time of writing, the company’s stock has experienced a tremendous influx, with shares being traded at a rate eight times higher than their float. A remarkable 16.2 million shares have exchanged hands, indicating substantial investor interest and enthusiasm.

The merger combines their expertise and resources to advance their late-stage oncology pipeline. The merged company will operate under “TuHURA Biosciences, Inc.” and trade on The Nasdaq Capital Market. The transaction is expected to be completed in the third quarter of 2023.

The combined company will focus on advancing Morphogenesis’s two technologies that aim to overcome the limitations of current immunotherapies in treating cancer. These technologies include personalized cancer vaccines called Immune Fx (IFx) and tumor microenvironment modulators. IFx is designed to activate the immune response against patient-specific tumor antigens, while the tumor microenvironment modulators target myeloid-derived suppressor cells (MDSCs) to address resistance to immunotherapies.

The merger is seen as a promising opportunity to develop new therapies to overcome resistance to current immunotherapies, a significant unmet need in cancer treatment.

To Discover the Inside Scoop on CWBR, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The merger agreement includes terms for the stockholders of both companies and a $15 million private placement is expected to be conducted alongside the merger. The proceeds from the private placement will be used to fund the development pipeline of the combined company, with sufficient funds expected to last until 2024.

The merger has been approved by the boards of directors of both companies and is subject to stockholder approval and customary closing conditions. Following the merger, the combined company will be headquartered in Tampa, Florida, with Dr. James Bianco as Chief Executive Officer and Dan Dearborn as Chief Financial Officer. The board of directors will consist of seven members, five designated by Morphogenesis and two by CohBar.

More on the Pipeline

  • Immune Fx (IFx) Personalized Cancer Vaccines: IFx is designed to prime and activate an innate immune response against patient-specific tumor antigens, overcoming primary resistance to checkpoint inhibitors. Morphogenesis is currently preparing for a single Phase 2/3 registration trial of its lead personalized cancer vaccine, IFx-Hu2.0, as an adjunct to Keytruda® (pembrolizumab) in first-line treatment for advanced Merkel Cell Carcinoma (MCC). This study is expected to be conducted under a Special Protocol Assessment (SPA) agreement with the FDA and to commence in early 2024. Additionally, Morphogenesis is advancing IFx-Hu3.0, its mRNA vaccine, toward IND-enabling studies in 2024 to treat aggressive diffuse large B-cell lymphoma (DLBCLs).
  • Tumor Microenvironment (TME) Modulators: TME Modulators are designed to address one of the primary causes of acquired resistance to immunotherapies, including checkpoint inhibitors or cellular therapies like CAR-T. Leveraging its new class of novel bi-functional antibody-drug conjugates (ADCs), Morphogenesis is targeting a recently identified delta receptor on myeloid-derived suppressor cells (MDSCs). MDSCs comprise a major component of cells in the tumor microenvironment and are responsible for suppressing the immune system’s attack against the tumor. Morphogenesis is constructing several MDSC-targeted, bi-functional ADCs for in vitro and in vivo characterization, targeting lead selection by the end of 2024.

In conclusion, the proposed merger between CohBar and Morphogenesis represents a significant step forward in advancing personalized cancer vaccines and tumor microenvironment modulators. With Morphogenesis’ Immune Fx (IFx) Personalized Cancer Vaccines and Tumor Microenvironment (TME) Modulators, there is great potential to overcome resistance to current immunotherapies and improve treatment outcomes for patients with various cancers. The merger agreement, subject to stockholder approval, will result in a combined company named TuHURA Biosciences, with a strong management team and a focus on advancing the late-stage oncology pipeline. The transaction, backed by Ladenburg Thalmann & Co., Inc., and H.C. Wainwright & Co., is expected to close in the third quarter of 2023, paving the way for innovative advancements in cancer treatment.

We will update you on CWBR when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by naor eliyahu from Pixabay

Continue Reading

Emerging Markets

Aemetis Inc. (NASDAQ: AMTX) Pioneers Renewable Fuel Market with EPA Approval

Published

on

Aemetis (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the EPA.

Aemetis, Inc. (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the U.S. EPA to generate renewable identification numbers (RINs) under the federal Renewable Fuel Standard. They have six dairy biogas digesters up and running, with a seventh one scheduled to start operating in June 2023.

Aemetis plans to generate multiple sources of revenue from its renewable natural gas. They will sell the gas to replace petroleum diesel in transportation, sell California Low Carbon Fuel Standard credits to fuel blenders who need to meet carbon reduction requirements in California, sell the RINs generated under the federal Renewable Fuel Standard, and benefit from production tax credits starting in 2025 under the Inflation Reduction Act.

They have completed constructing and operating six dairy digesters, a biogas pipeline spanning over 40 miles, a central facility to upgrade biogas to renewable natural gas, and a utility pipeline interconnection unit. The renewable natural gas is injected into the utility gas system and stored underground until Aemetis Biogas obtains carbon intensity (CI) pathway approvals from the California Air Resources Board (CARB) to sell credits under the California Low Carbon Fuel Standard.

They have already completed 90 days of renewable natural gas production and data collection required for the CARB approval process. While the final pathway is under review by CARB, Aemetis can use a temporary CI pathway with a value of -150, allowing them to start generating revenue in the third quarter of 2023.

To Discover the Inside Scoop on AMTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Andy Foster, the president of Aemetis Biogas Inc., expressed excitement about the approval of Aemetis Biogas for generating D3 RINs, as it marks a significant milestone towards generating full product revenue. He emphasized that the company’s investments since 2019 have directly reduced greenhouse gas pollution, improved air quality in Central Valley communities, and created jobs. Aemetis is committed to expanding their network of dairy digesters and producing more carbon-negative renewable natural gas to replace petroleum diesel.

The dairy digesters, pipeline project, and biogas-to-RNG facility funding includes grants from the California Department of Food and Agriculture and the California Energy Commission. Aemetis also closed a $25 million long-term financing deal with Greater Commercial Lending last fall, supported by a loan guarantee from the USDA. This project financing has a low fixed interest rate for the first five years and spans over 20 years.

Aemetis has plans to file applications for an additional $100 million of loans from the USDA’s REAP loan program. These funds will support the engineering, permitting, and construction of 31 more dairies. Each loan application will be limited to a maximum of $25 million and carry a 20-year repayment term.

https://twitter.com/Theweedfarmer/status/1658946668052504576?s=20

Where could Aemetis, Inc. (NASDAQ: AMTX) be in 5 years?

The company has an ambitious Five Year Plan to generate substantial revenue and reduce air and carbon pollution. The plan projects $2.0 billion in revenues, $496 million in net income, and $682 million in adjusted EBITDA by 2027, with strong compound annual growth rates. Aemetis aims to expand its operations by producing Renewable Natural Gas (RNG), Sustainable Aviation Fuel (SAF), Renewable Diesel fuel (RD), and other low-carbon products. The plan emphasizes the positive financial impact of the Inflation Reduction Act.

The plan highlights the financial benefits of the Inflation Reduction Act, which enables the transfer of tax credits and incentives related to production, projected to improve net income by $341 million in 2027.

The plan also focuses on revenue growth in all product lines, including expanding the dairy RNG business, constructing a renewable jet/diesel plant, implementing carbon sequestration, and improving energy efficiencies. 

The company has already achieved significant milestones, such as completing biogas pipeline construction, upgrading facilities for biogas-to-RNG production, and progressing in carbon sequestration and renewable jet/diesel plant development. The company has also secured a biodiesel purchase agreement in India and made strides in constructing a solar microgrid and implementing energy-efficient measures.

We will update you on AMTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Leopold Böttcher from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.